United States Hemorrhoid Treatment Devices - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The united states hemorrhoid treatment devices market size was valued at USD 311.08 million in 2025 and is estimated to grow from USD 327.85 million in 2026 to reach USD 437.06 million by 2031, at a CAGR of 5.92% during the forecast period (2026-2031). This report is Segmented by Product Type (Band Ligators, Infrared Coagulators, Sclerotherapy Injectors, Bipolar Probes, Cryotherapy Devices, Laser Probes), Procedure Type (Non-Surgical Procedures, Minimally Invasive Surgical Procedures, Conventional Hemorrhoidectomy), and End User (Hospitals, and More). The Market Forecasts are Provided in Terms of Value (USD).

United States Hemorrhoid Treatment Devices Market Trends and Insights

Rising Incidence of Symptomatic Hemorrhoids in Adults Over 50

The United States hemorrhoid treatment devices market continues to draw support from age-linked disease prevalence and a large untreated patient base. Current guidance states that nearly half of Americans develop symptomatic hemorrhoids by age 50, and the condition affects 10.4 million people in the country at any given time. The same source indicates that 1 million new cases arise each year, and 10% to 20% of those patients require procedural treatment. Medicare fee-for-service data also show hemorrhoid-associated diagnoses in 4.2% of beneficiaries aged 65 to 84, with the highest burden in the 70 to 74 group, which keeps the age-driven demand base intact for the United States hemorrhoid treatment devices market. This means future volume in the United States hemorrhoid treatment devices market depends not only on prevalence, but also on how effectively office procedures can convert symptomatic patients into treated cases.

Shift Toward Minimally Invasive and Outpatient Treatment Pathways

The United States hemorrhoid treatment devices market is moving further toward minimally invasive care because current ASCRS guidance identifies rubber band ligation as the most effective office-based option for symptomatic grade I to grade III internal hemorrhoids. The guideline review cites an 86.7% asymptomatic rate at 8 weeks in a 2,635-patient retrospective series, which reinforces the appeal of office procedures that avoid operating room use for a large share of patients. This treatment pattern is redirecting procurement toward band ligators, anoscopes, and sclerotherapy injector kits rather than hospital-centered surgical instrumentation. Sclerotherapy is also gaining ground, because polidocanol foam has shown 98% symptom resolution at 4 weeks in a prospective 2,000-patient series and 95.6% success at 1 year in a phase II multicenter trial. As a result, the United States hemorrhoid treatment devices market is broadening beyond banding alone and is creating room for newer office-ready injector platforms.

Limited Specialist Access in Rural and Underserved Areas

The United States hemorrhoid treatment devices market continues to face a structural access constraint in countries with limited specialist coverage. A 2026 study in Digestive Diseases and Sciences found that more than two-thirds of 3,149 US counties lacked a gastroenterologist, and 49 million to 50 million Americans lived more than 25 miles from GI specialty care. In 2025, non-metropolitan areas had a gastroenterologist workforce adequacy of only 29.7%, compared with 106% in metropolitan areas, and the South remained the weakest region, even within metro geographies, at 87% adequacy. The same access problem is likely to persist because more than two-thirds of rural GI specialists were older than 55, and nearly half were older than 65, which points to additional retirement pressure on procedural capacity. Rural primary care constraints reinforce the same issue, as 66.3% of all primary care Health Professional Shortage Areas were in rural locations as of September 2024.

Other drivers and restraints analyzed in the detailed report include:

• Expansion of Outpatient Procurement, Reimbursement Support, and Single-Use Formats
• Patient Preference for Home Recovery and Lower-Discomfort Treatment
• OTC Substitution, Reimbursement Friction, and Sustainability Pressure

Segment Analysis

Band ligators held 34.48% of the United States hemorrhoid treatment devices market share in 2025, which kept them in the leading product position. Their position reflects continued endorsement in ASCRS guidance, a well-defined office procedure role, and established reimbursement support for routine banding. The product class also benefits from continued movement toward disposable and pre-loaded systems, with platforms such as the CRH O’Regan System built around office and outpatient workflow efficiency. Infrared coagulators, sclerotherapy injectors, and bipolar probes remain clinically relevant in grade I to grade II disease, in anticoagulated patients, and in adjunctive procedural settings where banding is not the only preferred choice.

Cryotherapy devices are the fastest-growing product segment, and this part of the United States hemorrhoid treatment devices market size is projected to rise at a 7.36% CAGR through 2031. The CYPHER trial gave this category stronger clinical support by showing lower early postoperative pain after grade III hemorrhoidectomy when intra-anal cryotherapy was used. FDA 510(k) clearances for the XSense Cryoablation System and the Co-Ablation System in 2024 showed that the regulatory channel remains open for newer cryotherapy options in proctology. Laser probes still hold a smaller current position, but they are gaining interest as hospitals and advanced outpatient centers adopt consoles that address grade II to grade IV disease with a lower pain profile than conventional excisional approaches in selected cases.

Complete Report Scope:

• By Product Type
  • Band Ligators
  • Infrared Coagulators
  • Sclerotherapy Injectors
  • Bipolar Probes
  • Cryotherapy Devices
  • Laser Probes
• By Procedure Type
  • Non-Surgical Procedures
  • Minimally Invasive Surgical Procedures
  • Conventional Hemorrhoidectomy
• By End User
  • Hospitals
  • Ambulatory Surgical Centers
  • Specialty Clinics and Colorectal Centers

List of Companies Covered in this Report:

• A.M.I. Agency for Medical Innovations GmbH
• B. Braun
• Boston Scientific
• Conmed
• Cook Group
• Ethicon, Inc.
• Halyard Health, Inc.
• Integra LifeSciences
• Johnson & Johnson
• Karl Storz SE and Co. KG
• Medtronic
• OBP Surgical
• Olympus
• Privi Medical Pte. Ltd.
• Redfield Corporation
• Sklar Surgical Instruments
• Smiths Group
• Surkon Medical Co. Ltd.
• Teleflex
• Ultroid Technologies, LLC

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support